摘要目的 研究食管癌浸润深度的相关危险因素,为食管癌浸润深度提供更加准确的判断方法。方法 回顾性分析2014年6月至2020年6月于郑州大学第二附属医院行胃镜+病理检查确诊为食管癌,并行手术治疗的174例患者,其中男性102例(58.6%),女性72例(41.4%),共计病灶174处。观察并记录符合纳入标准患者的年龄、性别、肿瘤部位、肿瘤大小、术前血小板淋巴细胞比值(PLR)、中性粒细胞淋巴细胞比值(NLR)、淋巴细胞单核细胞比值(LMR)及术后病理诊断结果。结果 高PLR与浸润深度相关(>SM1 vs ≤SM1:OR=1.017,95%CI=1.006~1.028,P=0.002);肿瘤长度与浸润深度相关(>SM1 vs ≤SM1:OR=1.581,95%CI=1.234~2.024,P<0.001)。PLR、肿瘤长度诊断肿瘤浸润深度中,曲线下面积(AUC)分别为0.74、0.796;敏感度分别为0.495、0.722;特异性分别为0.883、0.714。两者联合诊断,AUC为0.812,敏感度为0.866,特异性为0.61。结论 PLR、肿瘤长度诊断食管癌浸润深度都具有较好的准确性,两者联合可使准确性进一步提高,为治疗方案的选择提供较为可靠的依据。
Abstract：Objective: To study the related risk factors inherent in the invasive depth of esophageal cancer,and provide a more accurate method to judge the invasive depth of esophageal cancer. Methods: A total of 174 patients (174 lesions) diagnosed with esophageal cancer via gastroscopy and pathological diagnosis in the Second Affiliated Hospital of Zhengzhou University from June 2014 to June 2020,including 102 males (58.6%),72 females (41.4%),were retrospectively analyzed. The age,gender,tumor location,tumor size,preoperative PLR,NLR,LMR and postoperative pathological diagnosis were observed and recorded. Results: High PLR was significantly correlated with the depth of invasion (> SM1 vs ≤SM1:OR=1.017,95% CI=1.006 ~ 1.028,P = 0.002); tumor length was significantly correlated with the depth of invasion (> SM1 vs ≤SM1:OR=1.581,95% CI=1.234 ~ 2.024,P<0.001),where AUC was 0.74 and 0.796. The sensitivity was 0.495 and 0.722,and the specificity respectively was 0.883 and 0.714. The AUC,sensitivity and specificity of PLR combined with tumor length was 0.812,0.866 and 0.61. Conclusion: PLR and tumor length are accurate in their diagnostic capabilities for the depth of the invasion of esophageal cancer,and their combination can further improve accuracy and provide a more reliable basis for treatment options.
丁丹丹, 周英发, 黄琳凯. 食管癌浸润深度相关危险因素分析[J]. 河北医学, 2021, 27(3): 436-439.
DING Dandan, ZHOU Yingfa, HUANG Linkai. An Analysis of Risk Factors Related to the Depth of Invasion in Esophageal Carcinoma. HeBei Med, 2021, 27(3): 436-439.
[1] Bray F,Ferlay J,Soerjomataram I,et a1.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer Clin,2018,68(6):394~422. [2] Thrumurthy SG,Chaudry MA,Thrumurthy SSD,et al.Oesophageal cancer:risks,pre-vention,and diagnosis[J].BMJ,2019,366:l4373. [3] 中华医学会消化内镜学分会消化系早癌内镜诊断与治疗协作组,中华医学会消化病学分会消化道肿瘤协作组,中华医学会消化病学分会消化病理学组.中国早期食管鳞状细胞癌及癌前病变筛查与诊治共识(2015年·北京)[J].中国实用内科杂志,2016,36(1):20~33. [4] 中国临床肿瘤学会指南工作委员会.食管癌诊疗指南(2020版)[M].北京:人民卫生出版社,2020. [5] Toyokawa T,Kubo N,Tamura T,et al.Platelet to lymphocyte ratio is a predict-ive marker of prognosis and therapeutic effect of postoperative chemothera-py in non-metastatic esophageal squamous cell carcinoma[J].Clin Chim Acta,2018,479:160~165. [6] Yang J,Liu Y,Li B,et al.Prognostic significance of tumor length in patientswith esophageal cancer undergoing radical resection:a PRISMA-compliant me-ta-analysis[J].Medicine (Baltimore),2019,98(14):e15029. [7] Rice TW,Ishwaran H,Hofstetter WL,et al.Recommendations for pathologic stag-ing (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals[J].Dis Esophagus,2016,29(8):897~905. [8] Arigami T,Uchikado Y,Omoto I,et al.Primary tumor score based on tumor depthand length predicts prognosis in esophageal squamous cell carcinoma[J].Ant-icancer Res,2018,38(9):5447~5452. [9] Sun Y,Zhang L.The clinical use of pretreatment NLR,PLR,and LMR in patients with esophageal squamous cell carcinoma:evidence from a meta-analysis[J]. Cancer Manag Res,2018,10:6167~6179. [10] Kitagawa Y,Uno T,Oyama T,et al.Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society:Part 1[J].Esophagus,2019,16(1):1~24. [11] Mashimo H,Gordon SR,Singh SK.Advanced endoscopic imaging for detecting and guiding therapy of early neoplasias of the esophagus[J].Ann N Y Acad Sci,2020,1482(1):61~76.
2021, Vol. 27 
冀公网安备13080202000677号